Status:
UNKNOWN
Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection
Lead Sponsor:
Incheon St.Mary's Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
19-75 years
Phase:
NA
Brief Summary
This study aims to investigate eradication rate, drug compliance, and adverse events in patients with confirmed Helicobacter pylori infection between tegoprazan, bismuth, metronidazole, and tetracycli...
Detailed Description
This is a multi-center, double-blind, randomized, active-controlled study.
Eligibility Criteria
Inclusion
- patients who male or female aged 19 to 75 years old and fall under the following conditions with confirmed helicobacter pylori infection
Exclusion
- patients who have H.pylori eradication history
- patients with history of gastric cancer surgery
- patients who have taken antibiotics within 4 weeks prior to trial
- a person who taking HIV protease inhibitors (atazanavir, nelfinavir) or a drug containing rilpivirine
- pregnant or breastfeeding women
Key Trial Info
Start Date :
March 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT04674774
Start Date
March 4 2021
End Date
March 31 2022
Last Update
February 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Incheon St. Mary's Hospital
Incheon, South Korea